Literature DB >> 21911292

Beyond the frog: the evolution of homology models of human IKKβ.

Nicholas Y Palermo1, Amarnath Natarajan.   

Abstract

Nuclear Factor κ B is implicated in tumor progression and chronic inflammatory diseases and is regulated by IκB kinase β (IKKβ). The crystal structure of IKKβ has been recently solved for Xenopus laevis. Homology models of human IKKβ have been developed prior to and after the crystal structure was solved. Here, we compare four models of human IKKβ and evaluate their performance in both broad and focused library docking studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911292      PMCID: PMC3177977          DOI: 10.1016/j.bmcl.2011.08.051

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

Review 4.  IkappaB kinase complexes: gateways to NF-kappaB activation and transcription.

Authors:  Claus Scheidereit
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

Review 5.  Shared principles in NF-kappaB signaling.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

6.  Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1.

Authors:  Toshiki Murata; Mitsuyuki Shimada; Sachiko Sakakibara; Takashi Yoshino; Hiroshi Kadono; Tsutomu Masuda; Makoto Shimazaki; Takuya Shintani; Kinji Fuchikami; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Toshiro Niki; Masaomi Umeda; Kevin B Bacon; Karl B Ziegelbauer; Timothy B Lowinger
Journal:  Bioorg Med Chem Lett       Date:  2003-03-10       Impact factor: 2.823

7.  Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents.

Authors:  Toshiki Murata; Mitsuyuki Shimada; Sachiko Sakakibara; Takashi Yoshino; Tsutomu Masuda; Takuya Shintani; Hiroki Sato; Yuji Koriyama; Keiko Fukushima; Noriko Nunami; Megumi Yamauchi; Kinji Fuchikami; Hiroshi Komura; Akihiko Watanabe; Karl B Ziegelbauer; Kevin B Bacon; Timothy B Lowinger
Journal:  Bioorg Med Chem Lett       Date:  2004-08-02       Impact factor: 2.823

8.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor.

Authors:  P A Baeuerle; D Baltimore
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

9.  Crystal structure of inhibitor of κB kinase β.

Authors:  Guozhou Xu; Yu-Chih Lo; Qiubai Li; Gennaro Napolitano; Xuefeng Wu; Xuliang Jiang; Michel Dreano; Michael Karin; Hao Wu
Journal:  Nature       Date:  2011-03-20       Impact factor: 49.962

10.  The SWISS-MODEL Repository and associated resources.

Authors:  Florian Kiefer; Konstantin Arnold; Michael Künzli; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2008-10-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.